1Fisher B,Costantino JP, Wickerham DL,et al.Tamoxifen for prevention ofbreast cancer: report of the National Surgical AdjuvantBreast and Bowel Project P2I Study[J].J Natl Cancer Inst,1998,90(18): 1371-1388.
4Peto R.ATLAS(adjuvant tamoxifen,longer against shorter): Intemational randomized trial ofl0 vs 5 years of adjuvant tamoxifen among 11500 women -Preliminary results[C].SABCS, 2007,Abstract#48.
6Locci P, Bellocchio S,Lilli C,et al.Synthesis and secretion of transforming growth factor-betal by human desmoids fibroblastcell line and its modulation by toremifene[J].J Interferon Cytokine Res,2001,21 (11):961-970.
7Hong A,Leigh 13R.Antiproliferative properties of toremifene on ADS-related Kaposi' s sarcoma ceUs[J].Chemotherapy,2002,48 (5):238-243.
3Bolufer P, Ricart E, Lluch A, et al. Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol, 1992,10(3) :438-446.
4Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone- sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol,2002,13 (2) :293-298.
5Dixon JM,Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer, 2002,38 ( 17 ) :2214-2221.
6Eiemann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol, 2001, 12 ( 11 ) : 1527- 1532.
7Olson JA Jr, Budd GT, Carey LA, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy:results from a multicenter phase Ⅱ trial. J Am Coll Surg,2009, 208(5) :906-914.
8Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination : the immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen(IMPACT) muhicenter double-blind randomized trial. J Clin Oncol, 2005, 23(22) :5108-5116.
9Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-Positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen ( PROACT ) trial. Cancer, 2006, 106(10) :2095-2103.
10Mlineritsh B, Tausch El. Exemcstane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase Ⅱ trial of the Austrian Breast and Colorectal Cancer Study Group( ABCSG- 17 ). Breast Cancer Res Treat, 2008,112 ( 1 ) : 203- 213.
